BET-PROTAC led to a prolonged and profound decrease of BET proteins (including BRD4) in post-myeloproliferative (post-MPN) AML cell lines and patient-derived post-MPN AML cells, compared to BETi at equimolar concentrations. This evidence concerns the gene BRD4 and acute myeloid leukemia.